Garuda Therapeutics
PrivateLast Round
Series A
Extension
Mar 4, 2025
Total Funding Raised
$184M
Company Overview
Garuda Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series A Extension round in March 2025.
Garuda Therapeutics is a biotechnology company that develops off-the-shelf hematopoietic stem cell therapies to treat blood, bone marrow, immune, and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Garuda Therapeutics Comparables
Compare Garuda Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Stratus Therapeutics | 100% | |
| Cell BioEngines, Inc. | 87% | |
| GC Therapeutics | 77% |
For institutional investors. Book with your work email.
Garuda Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Mar 4, 2025 | ||||
| Series B | Feb 7, 2023 | ||||
| Series A | Sep 23, 2021 |
For institutional investors. Book with your work email.
Garuda Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ridgeback Capital | Series A |
| Cormorant Asset Management | Series A Extension, Series A, Series B |
| Mass General Brigham Innovation | Series B, Series A |
| OrbiMed | Series A Extension, Series B, Series A |
| Cormorant Capital | Series A |
| Northpond Ventures | Series A Extension, Series B, Series A |
| Alexandria Venture Investments | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 4, 2025
$50M raised in Series A Extension round.
- Mar 3, 2025
Avanish Vellanki appointed as new President and Chief Executive Officer.
For institutional investors. Book with your work email.
Garuda Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Garuda Therapeutics's valuation, stock price, and market status.
Is Garuda Therapeutics a public or private company?
Garuda Therapeutics is a private company.
What is the current stock price of Garuda Therapeutics?
Garuda Therapeutics is a private company, so its shares have no public market price. Caplight tracks Garuda Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Garuda Therapeutics worth (valuation)?
Valuation information for Garuda Therapeutics is not publicly available.
Can I buy Garuda Therapeutics stock?
Garuda Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Garuda Therapeutics's last funding round?
Garuda Therapeutics's most recent funding round was Series A Extension on March 4, 2025.
Who are the main investors in Garuda Therapeutics?
Key investors in Garuda Therapeutics include Cormorant Asset Management, OrbiMed, Northpond Ventures, Aisling Capital, Northpond Ventures.
Will Garuda Therapeutics IPO soon?
No public IPO plans have been announced for Garuda Therapeutics.
How can I track Garuda Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Garuda Therapeutics's shares on secondary markets.